Aurinia Pharmaceuticals Inc. (AUPH) Stock Price Down 3.7%
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) fell 3.7% on Thursday . The company traded as low as $2.26 and last traded at $2.35, with a volume of 1,531,332 shares. The stock had previously closed at $2.44.
A number of research firms recently weighed in on AUPH. FBR & Co reissued an “outperform” rating and set a $9.00 target price on shares of Aurinia Pharmaceuticals in a research report on Monday. Canaccord Genuity set a $10.00 target price on Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 5th. Leerink Swann reissued an “outperform” rating and set a $7.00 target price on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 6th. HC Wainwright began coverage on Aurinia Pharmaceuticals in a research report on Thursday, June 30th. They set a “buy” rating and a $7.00 target price on the stock. Finally, Zacks Investment Research downgraded Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, May 5th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $7.75.
The firm’s market capitalization is $79.75 million. The company has a 50-day moving average price of $3.17 and a 200 day moving average price of $2.78.
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.